Johnson & Johnson's New Drug Trial Successful, Significant Improvement in Psoriasis Patients' Skin Condition
Johnson & Johnson announced on Monday that in a late-stage clinical trial, the company's oral drug for the treatment of specific skin conditions has achieved its primary goal of significantly improving the condition of the skin to a point where it is clear or near clear and reducing the formation of skin plaques.
The drug, icotrokinra, is a once-daily pill whose efficacy has been demonstrated in patients with moderate to severe plaque psoriasis. Plaque psoriasis is a skin disease that causes dry, itchy patches of skin.
Johnson & Johnson is working to develop new treatments because its current top-selling drug, Stelara, is about to expire and a cheaper biosimilar will be available.
In the pharmaceutical industry, companies such as AbbVie and Johnson & Johnson (J&J) are competing for market share in an increasingly crowded market for treatments for inflammatory diseases.
At week 16 of the trial, icotrokinra demonstrated significant skin clearance in 64.7% of patients, while a reduction in plaque severity was observed in 49.6% of subjects. That compared with 8.3 percent and 4.4 percent for the placebo group.
The drug works by targeting IL-23, a protein associated with inflammation.
Johnson & Johnson developed icotrokinra with partner Protagonist Therapeutics. Based on the trial results, Protagonist Therapeutics is now eligible for a milestone payment of up to $165 million.
Johnson & Johnson also said it plans to initiate a late-stage clinical trial of icotrokinra for psoriatic arthritis in early 2025.
In the United States, about 7.5 million people have psoriasis, and 80 to 90 percent of these cases are plaque psoriasis, the most common type of the disease.
2026-10-25
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
INEOS Closes US Polystrene Plant: 400K Tons of PD in the US Can't Hold On
-
Lotte Merges with HD Hyundai: Can Korea’s Petrochemical First Case Trigger True Restructuring?
-
Evonik Cuts 3,200 Jobs: Europe’s Chemical Winter Is Not Over
-
As Middle East Supply Faces Disruptions, SABIC's 1.8 Million Mt/Year Methanol New Project Secures Saudi Feedstock Quota
-
South Korea Moves Urgently to Control Petrochemical Feedstock Hoarding as Supply Chain Risk Escalates to the National Security Level
-
Dow Swings from an $801 Million Loss to an $802 Million Profit as Hormuz Disruption Lifts Polyethylene Prices
-
Türkiye Advances $3 Billion Petrochemical Cluster Targeting 17% of Domestic Polypropylene Demand
-
Argentina to Build Latin America’s Largest Urea Plant Under €1.3 Billion Contract
-
Hormuz Crisis Pushes Up Urea Prices as Yara’s Quarterly EBITDA Jumps 39%
-
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
Recommend Reading
-
After Two Price Hikes in One Week, Dow Has Fully Exposed the Most Sensitive Nerve in Europe’s Polyurethane Market
-
IMCD Opens Beauty and Personal Care Lab in California
-
Westlake Acquires ACI's Composites Business to Expand Global Footprint
-
“Shutdown Equals Price Hike”: TDI Market Enters a New Era of “Scarcity Games”
-
LyondellBasell's 230,000-tonne PP Plant Permanently Shut Down
-
Cost Reversal & Weak Supply and Demand: Polypropylene Prices Consolidate at High Levels
-
Business Society, September 24, 2026: ABS Market Outlook – Volatile and Bearish
-
This week, the market price of pure benzene in China has risen (9.21-9.24)
-
On March 9, the Isopropyl Alcohol Market in China Experienced a Significant Price Increase
-
Business Society September 24, 2026 Hydrogen Peroxide Trend Analysis: Clearly Downward